P Peptide Calculator
Need a Reliable Peptide Supplier? Click HERE!!!SponsoredVisit ↗
ARA-290 and Acetic Acid Mix

ARA-290 Reconstitution Calculator

Reviewed by · Pharmacist and Scientific Reviewer

Enter the amount you want to measure. The vial buttons will highlight which vial strengths create cleaner syringe-unit measurements.

⚠ Use acetic acid — not bacteriostatic water ARA-290 is insoluble or unstable in standard BAC water. Manufacturer protocols require reconstitution in dilute acetic acid (0.1%) — or, for IGF-1 variants, 50 mM acetic acid. Volumes shown below refer to acetic acid, not water.

What amount do you need?

Type the target amount, then choose mg or mcg. Example: 2mg or 500mcg.

Work the dose out from body weight

Syringe size:
Possible vial strengths:
Best Match Good Match Usable Harder to Measure

Example ARA-290 Titration Schedule

ItemDetails
Trial dose4 mg SC once daily
Duration28 days (course)
DurabilityBenefits persist ~9 months

The most clinically validated research peptide in this catalog (five human trials, clean safety). 4 mg was the only effective dose in the dose-ranging study (1 mg too low, 8 mg no better). Fixed 28-day courses replace '30-day cycles': the trial design is 28 days on, with benefit outlasting dosing by months.

Possible vial strengths:

What Is It?

ARA-290

Erythropoietin-derived peptide investigated for neuropathy.

Acetic Acid (0.1%)

A dilute solution of acetic acid (typically 0.1% for most peptides, or 50 mM for IGF-1 variants) used to reconstitute peptides that are insoluble or unstable in standard bacteriostatic water. ARA-290 requires an acidic carrier to dissolve fully and remain stable — plain BAC water will not work and may damage the peptide.

How To Mix ARA-290

1
Clean

Use alcohol swabs to clean the tops of both vials.

2
Draw Acetic Acid

Draw the selected amount of 0.1% acetic acid.

3
Inject Slowly

Add the liquid slowly down the side of the vial.

4
Swirl Gently

Do not shake. Swirl gently until dissolved.

5
Store Properly

Store as directed and protect from heat and light.

Best Practices & Common Mistakes

Best Practices

  • Use sterile technique.
  • Protect from light and heat.
  • Store refrigerated when appropriate.
  • Use clean syringe-unit math before measuring.

Common Mistakes

  • Confusing milligrams with milliliters.
  • Choosing an option with awkward decimal units.
  • Using too little liquid for very small measurements.
  • Shaking the vial aggressively.

ARA-290 Storage & Handling

Lyophilized Powder: −20°C (−4°F) for long-term storage (up to 24 months). Refrigeration 2–8°C (36–46°F) for short-term use (up to ~3 months). Original sealed vial in the freezer is safest.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.

Frequently Asked Questions

ARA-290 is an 11-amino-acid peptide cut from the tissue-protective part of erythropoietin (EPO). Unlike EPO, it doesn't raise red blood cells at all — it triggers only EPO's separate repair-and-anti-inflammatory pathway, so it sidesteps EPO's clotting and cardiovascular risks. It's studied mainly for nerve repair and neuropathic pain.
In published Phase 2 trials, ARA-290 was given at about 2–4 mg per day by subcutaneous injection. These are research figures from trial designs, not an approved regimen, and dosing is a clinical decision.
Add bacteriostatic water and swirl gently — don't shake. A 10 mg vial + 2 mL gives 5 mg/mL, so a 4 mg dose = 0.8 mL = 80 units on a U-100 syringe. Use the calculator above for your exact vial size (10 mg and 16 mg are common).
Its target, the innate repair receptor, appears at sites of injury and inflammation, and ARA-290 switches it on to calm inflammation and support small-fiber nerve repair rather than just numbing pain. Phase 2 trials in sarcoidosis- and diabetes-related small-fiber neuropathy reported less neuropathic pain and increased corneal nerve-fiber density — real human signals, which is unusual among research peptides. It even holds FDA orphan-drug status for sarcoidosis neuropathy.
ARA-290 has a favorable safety profile in the trials run so far, helped by the fact that it doesn't affect red blood cells — but those trials are small (around 100 patients total), so rare risks and long-term effects aren't known. Despite genuine Phase 2 data and orphan-drug status, it was never approved, the developer closed, and development stalled — promising signals, no finish line. Store the dry vial refrigerated and out of light; once mixed, keep cold and use within a few weeks.
Practical takeaway: If your goal involves weight management, metabolic health, recovery, physical performance, cognitive function, appearance, or general well-being, discuss it with a licensed healthcare professional. They can help you evaluate approved, evidence-based options rather than relying on an unapproved or investigational compound. This calculator is intended only for transparent research-reference calculations and does not determine an appropriate amount, recommend use, or replace professional medical guidance.

More Healing & Repair calculators

BPC-157 TB-500 GHK Basic GHK-Cu (Copper Peptide) LL-37 (CAP-18) KPV Thymagen B7-33

References

  1. Culver DA, et al. DOSARA dose-ranging study of cibinetide. Invest Ophthalmol Vis Sci. 2017.

About the author

· Pharmacist and Scientific Reviewer

Maria Hrabina is a pharmacist and scientific reviewer with a strong interest in peptide science, pharmacology, and emerging therapeutic compounds.

Her work focuses on understanding how peptide-based compounds interact with biological signaling pathways and how they are being investigated across areas such as metabolic health, dermatology, recovery, regenerative research, and pharmaceutical development.

Maria follows research on a broad range of peptides, from compounds used in approved medicines to experimental molecules still being evaluated in laboratory, preclinical, and clinical studies.

Her approach combines scientific curiosity with critical evaluation of evidence. She believes promising mechanisms and early research deserve attention, but should not be presented as established clinical benefits until they are supported by adequate human data.

Her areas of focus include scientific literature review, mechanisms of action, pharmacology, pharmacokinetics, safety, pharmaceutical formulation, and the overall quality of evidence behind peptide-based compounds.

She is particularly interested in the process of translating an experimental molecule into a reliable pharmaceutical product — including compound characterization, purity, stability, formulation, dose selection, safety assessment, and controlled clinical trials.

Maria believes peptide science has significant long-term potential, but that its progress depends on rigorous research, high manufacturing standards, transparent safety data, and responsible scientific communication.

Through her writing, she aims to help readers understand both sides of peptide research: what makes these compounds scientifically promising and what questions remain before their potential can be considered clinically established.

Areas of interest: Peptide Science · Therapeutic Peptides · Peptide Pharmacology · Metabolic Peptides · Cosmetic Peptides · Drug Development · Pharmacokinetics · Drug Safety · Pharmaceutical Formulation · Emerging Therapies · Evidence-Based Medicine

Important: This tool is for informational and research-reference purposes only. Not intended for human or veterinary use.
← All peptides